OncoSec Medical President and CEO, Punit Dhillon Publishes Blog Post Titled ''Building Relationships between Biotech Corporations and Academia''

Accesswire

OncoSec Medical Inc. (OTC Markets: ONCS.OB), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, published a blog post entitled “Building Relationships between Biotech Corporations and Academia” on Mr. Dhillon’s blog site (punitdhillon.com) which was republished on TheChairmansBlog.com.

OncoSec’s President and CEO, Punit Dhillon, writes about the importance of integrating academic institutions and their research potential with the research and development pipeline of biotech corporations. Mr. Dhillon believes that developing these “mutually beneficial relationships not only benefits the [start-ups and established pharmaceutical and life science companies] but also the general public, as better targeted and more effective treatment options become more readily available.” Taking advantage of such benefits, Mr. Dhillon outlines a few premier universities “with cutting edge efforts in oncology” the Company plans to collaborate with.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

View Comments